Skin Disorders, Including Pyoderma, Scabies, and Tinea Infections

Pediatric Clinics of North America

Volumn 56, Issue 6, 2009, Pages 1421-1440

  Andrews, Ross M ^a   McCarthy, James ^b,c   Carapetis, Jonathan R ^a   Currie, Bart J ^a  

^a MENZIES SCHOOL OF HEALTH RESEARCH   (Australia)

^b QIMR BERGHOFER MEDICAL RESEARCH INSTITUTE   (Australia)

^c UNIVERSITY OF QUEENSLAND   (Australia)

Author keywords

Pyoderma; Scabies; Skin diseases; Staphylococcal infections; Streptococcal infections; Tinea

Indexed keywords

ACARICIDE; AZITHROMYCIN; BENZATHINE PENICILLIN; BENZYL BENZOATE; CEFALEXIN; CHLORHEXIDINE; CLARITHROMYCIN; CLINDAMYCIN; CLOTRIMAZOLE; COTRIMOXAZOLE; CROTAMITON; DICLOXACILLIN; DOXYCYCLINE; ERYTHROMYCIN; FLUCLOXACILLIN; FLUCONAZOLE; FUSIDATE SODIUM; GRISEOFULVIN; IVERMECTIN; LINDANE; METICILLIN; NAFCILLIN; PENICILLIN G; PENICILLIN V; PERMETHRIN; POVIDONE IODINE; PSEUDOMONIC ACID; ROXITHROMYCIN; TERBINAFINE; UNINDEXED DRUG;

ANTIBIOTIC RESISTANCE; BACTERIUM CULTURE; BONE MARROW SUPPRESSION; CHILD; COMORBIDITY; CONSULTATION; CROWDING; DEATH; DISEASE TRANSMISSION; DOG; DOSAGE SCHEDULE COMPARISON; ENVIRONMENTAL SANITATION; EPILUMINESCENCE MICROSCOPY; ETHNICITY; EVIDENCE BASED MEDICINE; HAND WASHING; HEALTH CARE NEED; HOSPITALIZATION; HUMAN; INCIDENCE; INDIGENOUS PEOPLE; LIVER DYSFUNCTION; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MICROSCOPY; MICROSPORUM; NEUROTOXICITY; NEUTROPENIA; NONHUMAN; PATIENT COMPLIANCE; PERSONAL HYGIENE; POVERTY; PREVALENCE; PRIMARY HEALTH CARE; PYODERMA; REVIEW; SARCOPTES SCABIEI; SCABIES; SKIN BIOPSY; SKIN INFECTION; SOCIAL STATUS; STAPHYLOCOCCUS AUREUS; STREPTOCOCCUS PYOGENES; TERATOGENICITY; TINEA; TREATMENT DURATION; TRICHOPHYTON RUBRUM; TRICHOPHYTON TONSURANS; TRICHOPHYTON VIOLACEUM; ZOONOSIS;

ADMINISTRATION, CUTANEOUS; ADMINISTRATION, ORAL; ALGORITHMS; ANTI-BACTERIAL AGENTS; ANTIFUNGAL AGENTS; AUSTRALIA; CANADA; CHILD; CROWDING; DERMATOLOGIC AGENTS; DIAGNOSIS, DIFFERENTIAL; HUMANS; HYGIENE; INFUSIONS, INTRAVENOUS; INSECTICIDES; PERMETHRIN; POPULATION GROUPS; POVERTY; PRURITUS; PYODERMA; RISK FACTORS; SCABIES; TINEA; UNITED STATES;

EID: 71849094596     PISSN: 00313955     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.pcl.2009.09.002     Document Type: Review

References (75)

1. World Health Organization. The current evidence for the burden of group A streptococcal diseases. vol. WHO/FCH/CAH/05.07 (2005), World Health Organization, Geneva
2. Couzos S., and Currie B. Skin infections. In: Couzos S., and Murray R. (Eds). Aboriginal primary health care: an evidence-based approach. 2nd edition (2003), Oxford University Press, South Melbourne, Victoria 251-280
3. World Health Organization. Epidemiology and management of common skin diseases in children in developing countries (2005), World Health Organization, vol. WHO/FCH/CAH/05.12. Geneva
4. Anthony B.F., Perlman L.V., and Wannamaker L.W. Skin infections and acute nephritis in American Indian children. Pediatrics 39 (1967) 263-279
5. Hennessy T.W., Ritter T., Holman R.C., et al. The relationship between in-home water service and the risk of respiratory tract, skin, and gastrointestinal tract infections among rural Alaska natives. Am J Public Health 98 (2008) 2072-2078
6. Harris S.B., Glazier R., Eng K., et al. Disease patterns among Canadian aboriginal children. Study in a remote rural setting. Can Fam Physician 44 (1998) 1869-1877
7. Finger F., Rossaak M., Umstaetter R., et al. Skin infections of the limbs of Polynesian children. N Z Med J 117 (2004) U847
8. Steer A.C., Jenney A.W., Kado J., et al. High burden of impetigo and scabies in a tropical country. PLoS Negl Trop Dis 3 (2009) e467
9. Clucas D.B., Carville K.S., Connors C., et al. Disease burden and health-care clinic attendances for young children in remote aboriginal communities of northern Australia. Bull World Health Organ 86 (2008) 275-281
10. Bailie R.S., Stevens M.R., McDonald E., et al. Skin infection, housing and social circumstances in children living in remote Indigenous communities: testing conceptual and methodological approaches. BMC Public Health 5 (2005) 128
11. Tong S.Y., McDonald M.I., Holt D.C., et al. Global implications of the emergence of community-associated methicillin-resistant Staphylococcus aureus in Indigenous populations. Clin Infect Dis 46 (2008) 1871-1878
12. McDonald M.I., Towers R.J., Fagan P., et al. Molecular typing of Streptococcus pyogenes from remote Aboriginal communities where rheumatic fever is common and pyoderma is the predominant streptococcal infection. Epidemiol Infect 135 (2007) 1398-1405
13. Currie B.J., and Carapetis J.R. Skin infections and infestations in Aboriginal communities in northern Australia. Australas J Dermatol 41 (2000) 139-143
14. United Nations. The millennium development goals report 2008 (2008), United Nations, New York
15. Roberts L.J., Huffam S.E., Walton S.F., et al. Crusted scabies: clinical and immunological findings in seventy-eight patients and a review of the literature. J Infect 50 (2005) 375-381
16. Baltimore R.S. Treatment of impetigo: a review. Pediatr Infect Dis 4 (1985) 597-601
17. Demidovich C.W., Wittler R.R., Ruff M.E., et al. Impetigo. Current etiology and comparison of penicillin, erythromycin, and cephalexin therapies. Am J Dis Child 144 (1990) 1313-1315
18. Van Buynder P.G., Gaggin J.A., Martin D., et al. Streptococcal infection and renal disease markers in Australian aboriginal children. Med J Aust 156 (1992) 537-540
19. Carapetis J., Gardiner D., Currie B., et al. Multiple strains of Streptococcus pyogenes in skin sores of aboriginal Australians. J Clin Monit 33 (1995) 1471-1472
20. Vlack S., Cox L., Peleg A.Y., et al. Carriage of methicillin-resistant Staphylococcus aureus in a Queensland indigenous community. Med J Aust 184 (2006) 556-559
21. Darmstadt G.L., and Lane A.T. Impetigo: an overview. Pediatr Dermatol 11 (1994) 293-303
22. Bessen D.E., Carapetis J.R., Beall B., et al. Contrasting molecular epidemiology of group A streptococci causing tropical and nontropical infections of the skin and throat. J Infect Dis 182 (2000) 1109-1116
23. Chin J. Control of communicable diseases manual. An official report of the American Public Health Association. 17th edition (2000), American Public Health Association, Washington, DC
24. Taplin D., Porcelain S.L., Meinking T.L., et al. Community control of scabies: a model based on use of permethrin cream. Lancet 337 (1991) 1016-1018
25. Wong L.C., Amega B., Connors C., et al. Outcome of an interventional program for scabies in an Indigenous community. Med J Aust 175 (2001) 367-370
26. Carapetis J.R., Connors C., Yarmirr D., et al. Success of a scabies control program in an Australian aboriginal community. Pediatr Infect Dis J 16 (1997) 494-499
27. Lawrence G., Leafasia J., Sheridan J., et al. Control of scabies, skin sores and haematuria in children in the Solomon islands: another role for ivermectin. Bull World Health Organ 83 (2005) 34
28. Luby S.P., Agboatwalla M., Feikin D.R., et al. Effect of handwashing on child health: a randomised controlled trial. Lancet 366 (2005) 225-233
29. McCarthy J.S., Kemp D.J., Walton S.F., et al. Scabies: more than just an irritation. Postgrad Med J 80 (2004) 382-387
30. Mahé A., Faye O., N'Diaye H.T., et al. Definition of an algorithm for the management of common skin diseases at primary health care level in sub-Saharan Africa. Trans R Soc Trop Med Hyg 99 (2005) 39-47
31. Steer A.C., Tikoduadua L.V., Manalac E.M., et al. Validation of an integrated management of childhood illness algorithm for managing common skin conditions in Fiji. Bull World Health Organ 87 (2009) 173-179
32. La Vincente S., Kearns T., Connors C., et al. Community management of endemic scabies in remote aboriginal communities of Northern Australia: low treatment uptake and high ongoing acquisition. PLoS Negl Trop Dis 3 (2009) e444
33. Heukelbach J., Winter B., Wilcke T., et al. Selective mass treatment with ivermectin to control intestinal helminthiases and parasitic skin diseases in a severely affected population. Bull World Health Organ 82 (2004) 563-571
34. Gove S. Integrated management of childhood illness by outpatient health workers: technical basis and overview. The WHO Working Group on Guidelines for Integrated Management of the Sick Child. Bull World Health Organ 75 Suppl 1 (1997) 7-24
35. Koning S., Verhagen A.P., van Suijlekom-Smit L.W., et al. Interventions for impetigo. Cochrane Database Syst Rev 2 (2004) CD003261
36. Grayson M.L. The treatment triangle for staphylococcal infections. N Engl J Med 355 (2006) 724-727
37. Stevens D.L., Bisno A.L., Chambers H.F., et al. Practice guidelines for the diagnosis and management of skin and soft-tissue infections. Clin Infect Dis 41 (2005) 1373-1406
38. Taplin D., Lansdell L., Allen A.M., et al. Prevalence of streptococcal pyoderma in relation to climate and hygiene. Lancet 1 (1973) 501-503
39. Kar P., Shah B., and Raval R. Use of benzathine penicillin in impetigo in children. Indian J Dermatol Venereol Leprol 53 (1987)
40. Lan A.J., Colford J.M., and Colford Jr. J.M. The impact of dosing frequency on the efficacy of 10-day penicillin or amoxicillin therapy for streptococcal tonsillopharyngitis: a meta-analysis. Pediatrics 105 (2000) E19
41. Kiani R. Double-blind, double-dummy comparison of azithromycin and cephalexin in the treatment of skin and skin structure infections. Eur J Clin Microbiol Infect Dis 10 (1991) 880-884
42. Guchev I.A., Gray G.C., and Klochkov O.I. Two regimens of azithromycin prophylaxis against community-acquired respiratory and skin/soft-tissue infections among military trainees. Clin Infect Dis 38 (2004) 1095-1101
43. Central Australian Rural Practitioners Association. CARPA standard treatment manual (2003), Central Australian Rural Practitioners Association, Alice Springs (Australia)
44. Elliott D.J., Zaoutis T.E., Troxel A.B., et al. Empiric antimicrobial therapy for pediatric skin and soft-tissue infections in the era of methicillin-resistant Staphylococcus aureus. Pediatrics 123 (2009) e959
45. Strong M., and Johnstone P.W. Interventions for treating scabies. Cochrane Database Syst Rev 3 (2007) CD000320
46. Mellanby K. The development of symptoms, parasitic infection and immunity in human scabies. Parasitology 35 (1944) 197
47. Franz T.J., Lehman P.A., Franz S.F., et al. Comparative percutaneous absorption of lindane and permethrin. Arch Dermatol 132 (1996) 901-905
48. Basanez M.G., Pion S.D., Boakes E., et al. Effect of single-dose ivermectin on Onchocerca volvulus: a systematic review and meta-analysis. Lancet Infect Dis 8 (2008) 310-322
49. Guzzo C.A., Furtek C.I., Porras A.G., et al. Safety, tolerability, and pharmacokinetics of escalating high doses of ivermectin in healthy adult subjects. J Clin Pharmacol 42 (2002) 1122-1133
50. Chippaux J.P., Gardon-Wendel N., Gardon J., et al. Absence of any adverse effect of inadvertent ivermectin treatment during pregnancy. Trans R Soc Trop Med Hyg 87 (1993) 318
51. Gyapong J.O., Chinbuah M.A., and Gyapong M. Inadvertent exposure of pregnant women to ivermectin and albendazole during mass drug administration for lymphatic filariasis. Trop Med Int Health 8 (2003) 1093-1101
52. Paul A.J., Tranquilli W.J., Seward R.L., et al. Clinical observations in collies given ivermectin orally. Am J Vet Res 48 (1987) 684-685
53. Edwards G. Ivermectin: does P-glycoprotein play a role in neurotoxicity?. Filaria J 2 Suppl 1 (2003) S8
54. Roth W.I. Scabies resistant to lindane 1% lotion and crotamiton 10% cream. J Am Acad Dermatol 24 (1991) 502-503
55. Currie B.J., Harumal P., McKinnon M., et al. First documentation of in vivo and in vitro ivermectin resistance in Sarcoptes scabiei. Clin Infect Dis 39 (2004) e8-e12
56. Pasay C., Arlian L., Morgan M., et al. The effect of insecticide synergists on the response of scabies mites to pyrethroid acaricides. PLoS Negl Trop Dis 3 (2009) e354
57. Walton S.F., Myerscough M.R., and Currie B.J. Studies in vitro on the relative efficacy of current acaricides for Sarcoptes scabiei var. hominis. Trans R Soc Trop Med Hyg 94 (2000) 92-96
58. Hart R., Bell-Syer S.E., Crawford F., et al. Systematic review of topical treatments for fungal infections of the skin and nails of the feet. BMJ 319 (1999) 79-82
59. McClellan K.J., Wiseman L.R., and Markham A. Terbinafine. An update of its use in superficial mycoses. Drugs 58 (1999) 179-202
60. Jones T.C. Overview of the use of terbinafine (Lamisil) in children. Br J Dermatol 132 (1995) 683-689
61. Haroon T.S., Hussain I., Aman S., et al. A randomized double-blind comparative study of terbinafine for 1, 2 and 4 weeks in tinea capitis. Br J Dermatol 135 (1996) 86-88
62. Koh K.J., Parker C.J., Ellis D.H., et al. Use of terbinafine for tinea in Australian Aboriginal communities in the Top End. Australas J Dermatol 44 (2003) 243-249
63. Suchil P., Gei F.M., Robles M., et al. Once-weekly oral doses of fluconazole 150 mg in the treatment of tinea corporis/cruris and cutaneous candidiasis. Clin Exp Dermatol 17 (1992) 397-401
64. Carapetis J.R., Walker A.M., Hibble M., et al. Clinical and epidemiological features of group A streptococcal bacteraemia in a region with hyperendemic superficial streptococcal infection. Epidemiol Infect 122 (1999) 59-65
65. Norton R., Smith H.V., Wood N., et al. Invasive group A streptococcal disease in North Queensland (1996-2001). Indian J Med Res 119 Suppl (2004) 148
66. Kearns T., Evans C., and Krause V. Outbreak of acute post-streptococcal glomerulonephritis in the Northern Territory - 2001. NT Dis Control Bull 8 (2001) 6
67. White A.V., Hoy W.E., and McCredie D.A. Childhood post-streptococcal glomerulonephritis as a risk factor for chronic renal disease in later life. Med J Aust 174 (2001) 492-496
68. Rodriguez-Iturbe B., and Musser J.M. The current state of poststreptococcal glomerulonephritis. J Am Soc Nephrol 19 (2008) 1855-1864
69. McDonald M., Brown A., Edwards T., et al. Apparent contrasting rates of pharyngitis and pyoderma in regions where rheumatic heart disease is highly prevalent. Heart Lung Circ 16 (2007) 254-259
70. McDonald M., Currie B.J., and Carapetis J.R. Acute rheumatic fever: a chink in the chain that links the heart to the throat?. Lancet Infect Dis 4 (2004) 240-245
71. Martin D.R., Voss L.M., Walker S.J., et al. Acute rheumatic fever in Auckland, New Zealand: spectrum of associated group A streptococci different from expected. Pediatr Infect Dis J 13 (1994) 264-269
72. Carapetis J.R., Currie B.J., and Mathews J.D. Cumulative incidence of rheumatic fever in an endemic region: a guide to the susceptibility of the population?. Epidemiol Infect 124 (2000) 239-244
73. Carapetis J.R., McDonald M., and Wilson N.J. Acute rheumatic fever. Lancet 366 (2005) 155-168
74. Atkins D., Best D., Briss P.A., et al. Grading quality of evidence and strength of recommendations. BMJ 328 (2004) 1490
75. Guyatt G.H., Oxman A.D., Kunz R., et al. Going from evidence to recommendations. BMJ 336 (2008) 1049-1051